Will the FDA approve gedatolisib for advanced breast cancer?
gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancerScience
Will the FDA approve gedatolisib for advanced breast cancer?
gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancerScience
Kalshi Active 5 markets·81¢ Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?·$0 Total Volume·-- Liquidity·-- OI
22d 17h·Jul 8, 2026
Track your prediction positions
Connect your Kalshi account to track your contracts, P&L, and settlements.
Wide spread
No chart data available
Markets
5HR+/HER2-, PIK3CA wild-type before Jul 2027
$0 vol
HR+/HER2-, PIK3CA wild-type before Jan 2027
$0 vol
HR+/HER2-, PIK3CA wild-type before Aug 2026
$0 vol
HR+/HER2-, PIK3CA wild-type before Oct 2026
$0 vol
HR+/HER2-, PIK3CA wild-type before Jul 2026
$0 vol
HR+/HER2-, PIK3CA wild-type before Jul 2027
No order book data available
If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Jul 1, 2026, then the market resolves to Yes.
Track Your Bets on Kalshi — and Everything Else
Create a free portfolio starting with your Kalshi positions, P&L & live odds. Then add crypto wallets, exchanges, DeFi & more — all in one place.
Polymarket
Kalshi
50+ Chains
40+ Exchanges
DeFi
NFTs
16K+ Tokens
100% free· Read-only· Encrypted